808 MODELING HCV KINETICS DURING INTRAVENOUS SILIBININ MONOTHERAPY IN THE PERI-TRANSPLANT PERIOD

IU/mL, 45%/55% had severe fibrosis/cirrhosis, 28% had genotype 1a. Up to Week 16, 59% of patients developed grade 1–4 anemia (Hb 2.5 g/dL reduction), with 31% severe cases (Hb 4.5 g/dL reduction); 206 patients (34%) dose reduced ribavirin, 146 (24%) received EPO, 70 (11%) were transfused, 8 (1%) received iron-based products and 19 (3%) discontinued treatment for anemia. 122 patients (20%) had both a reduction in ribavirin dose and either EPO or a blood transfusion. Results by baseline disease stage are shown below: